SCHEMBL23723732

SCHEMBL23723732

CNCC(=O)N(C)c1ccc(Cl)c(Cl)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.48
HDAC3 O15379 1/20 0.45
HDAC1 Q13547 1/20 0.45
HDAC2 Q92769 1/20 0.45
HDAC6 Q9UBN7 1/20 0.45
GPBAR1 Q8TDU6 1/20 0.41
APEX1 P27695 1/20 0.41
KDM4E B2RXH2 2/20 0.39
LMNA P02545 1/20 0.39
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
CYP3A4 P08684 1/20 0.38
HPGD P15428 1/20 0.38
NR1H4 Q96RI1 1/20 0.38
SIGMAR1 Q99720 1/20 0.38
SLC6A2 P23975 1/20 0.38
SLC6A4 P31645 1/20 0.38
SLC6A3 Q01959 1/20 0.38
TSHR P16473 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18130476 0.84 ALDH1A1 (0.49) ALDH1A1HDAC3HDAC1HDAC2HDAC6
SCHEMBL9823820 0.82 ALDH1A1 (0.52) ALDH1A1HDAC3HDAC1HDAC2HDAC6
SCHEMBL19341421 0.82 ALDH1A1 (0.56) ALDH1A1HDAC3HDAC1HDAC2HDAC6
SCHEMBL7508139 0.81 DRD4 (0.47) ALDH1A1GPBAR1KMT2AMEN1CYP3A4
SCHEMBL15378617 0.81 AGPAT2 (0.50) ALDH1A1HDAC3HDAC1HDAC2HDAC6
SCHEMBL23723627 0.81 ALDH1A1 (0.48) ALDH1A1HDAC3HDAC1HDAC2HDAC6
SCHEMBL11399589 0.81 ALDH1A1 (0.48) ALDH1A1HDAC3HDAC1HDAC2HDAC6
SCHEMBL30120738 0.81 ALDH1A1 (0.48) ALDH1A1HDAC3HDAC1HDAC2HDAC6
SCHEMBL17336369 0.80 ALDH1A1 (0.47) ALDH1A1HDAC3HDAC1HDAC2HDAC6
SCHEMBL7052343 0.78 APEX1 (0.49) ALDH1A1HDAC3HDAC1HDAC2HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230140216-A1 COMBINATION THERAPY FOR TREATING MPS1 GAIN THERAPEUTICS SA (CH) 2023-05-04 US disclosed
US-20230140216-A1 COMBINATION THERAPY FOR TREATING MPS1 GAIN THERAPEUTICS SA (CH) 2023-05-04 US disclosed
US-20230140216-A1 COMBINATION THERAPY FOR TREATING MPS1 GAIN THERAPEUTICS SA (CH) 2023-05-04 US disclosed
EP-4100015-A1 COMBINATION THERAPY FOR TREATING MPS1 Gain Therapeutics SA (CH) 2022-12-14 EP disclosed
CN-115397423-A Combination therapy for the treatment of MPS1 增益治疗股份有限公司 2022-11-25 CN disclosed
WO-2021156774-A1 COMBINATION THERAPY FOR TREATING MPS1 GAIN THERAPEUTICS SA (CH) 2021-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230140216-A1 COMBINATION THERAPY FOR TREATING MPS1 IDUA, MAN2B1, GBA1 ALDH1A1 796/4885HDAC3 880/4885HDAC1 1350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.